A peptide engineered to go straight to your cells' power plants (mitochondria). It repairs the inner walls of your mitochondria, boosting energy production (ATP) by 20-40% and reducing harmful free radicals by 30-50%. Tested in over 500 patients in advanced clinical trials. Think of it as the foundation peptide -- by giving your cells more energy, it makes every other peptide work better too.
What to Expect
Week 1–2
Subtle increase in cellular energy. Improved exercise tolerance if mitochondrial dysfunction is present. Effects are at the cellular level initially.
Week 3–6
Noticeable improvement in stamina and energy. Reduced muscle fatigue. Better recovery from physical exertion. Improved mitochondrial biomarkers on labs.
Week 8+
Significant mitochondrial optimization. Improved cardiac function in those with dysfunction. Enhanced overall energy metabolism. Potential reversal of age-related mitochondrial decline.
Common Side Effects
Scientific Overview
SS-31 (Elamipretide, D-Arg-Dmt-Lys-Phe-NH2) is a mitochondria-targeted tetrapeptide that concentrates >1000-fold in mitochondrial inner membranes by binding to cardiolipin, a phospholipid unique to mitochondria. This interaction stabilizes cristae structure, optimizes electron transport chain efficiency, and reduces electron leak/ROS production. Phase 2/3 trials (500+ patients) in Barth syndrome and primary mitochondrial myopathy demonstrated safety at 4–40mg daily dosing for up to 28 weeks. SS-31 addresses the fundamental age-related decline in mitochondrial function.
Dosing
4-5 mg subq, 3 times a week on an empty stomach. Clinical trials showed it was safe at 4-40 mg daily for 28 weeks. Most people notice energy improvements within 3-7 days.
Practical Guide
Reconstitution
Mix vial per pharmacy instructions. Typically 5-40mg doses subcutaneously.
Storage
Refrigerate after reconstitution. Use within 14 days. Protect from light.
Injection Sites
Subcutaneous injection with insulin syringe. Daily dosing during treatment cycles.
Timing
Morning dosing preferred — aligns with mitochondrial activity peaks. Consistent daily timing.
Food
No known food interactions.
Benefit Profile
Medical Considerations
Contraindications
- ✕Pregnancy/nursing
- ✕Known hypersensitivity to peptide components
Drug Interactions
Recommended Monitoring
- →Renal function (cleared renally)
- →Cardiac monitoring if heart failure present
This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol.
Published Research
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.
Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.
Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.
Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.
Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.
A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.
Elamipretide: First Approval.
Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential.
Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects.